{
    "2021-05-01": [
        [
            {
                "time": "",
                "original_text": "太平洋维持华兰生物买入评级：血制品业务有望实现稳定增长，国内21年四价流感需求有望持续旺盛",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "血制品",
                        "稳定增长",
                        "四价流感",
                        "需求旺盛"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}